Apical membrane antigen 1 (AMA1) (AMA1)

Apical membrane antigen 1 (AMA1) is a critical type I integral membrane protein produced by Plasmodium falciparum, the primary causative agent of malaria. It is synthesized in the micronemes of merozoites and is subsequently translocated to the parasite surface during the invasion of host erythrocytes (UniProt P04913). AMA1 plays an essential role in the formation of the moving junction, a specialized structure required for parasite entry, by interacting specifically with the rhoptry neck protein 2 (RON2) (Srinivasan et al., 2011, PubMed: 21331064). Because this interaction is indispensable for the parasite's survival and the protein is exposed to the host immune system, AMA1 has been a major focus for blood-stage malaria vaccine development and the design of inhibitory peptides (Remarque et al., 2008, PubMed: 18248671). However, the high degree of genetic polymorphism in the AMA1 ectodomain allows the parasite to evade strain-specific immune responses, presenting a significant challenge for creating a broadly effective therapeutic (Takala et al., 2009, PubMed: 19443717). Current therapeutic strategies aim to target conserved regions of the AMA1-RON2 binding interface to overcome this allelic diversity.

Other names

PfAMA1Apical membrane antigen 1Merozoite surface antigen

Inhibition of the protein-protein interaction between AMA1 and Rhoptry Neck Protein 2 (RON2) to prevent the formation of the moving junction and subsequent entry into host erythrocytes.